Results 131 to 140 of about 2,198 (193)

A Novel Germline Deletion of p.C630 inRETCauses MTC and Promotes Cell Proliferation and Sensitivity to Pralsetinib [PDF]

, 2022
Xiao Ma, Xiuli Ma, Li‐Han Chin, Zhen Zhu, Haibo Han   +4 more
openalex   +1 more source

37P Pralsetinib in acquired RET fusion-positive advanced non-small cell lung cancer patients after resistance to EGFR/ALK-TKI: A China multi-center, real-world data (RWD) analysis [PDF]

, 2023
Junyi Hu, Xu-Dong Tang, Ran Guo, Ya-Yuan Wang, H. Shen, H. Wang, Yinghui Yao, Xinmeng Cai, Zhengyu Yu, G. Dong, F. Liang, Jiahui Cao, Lingyao Zeng, Marie W Su, Wentao KONG, L. Liu, Wen‐Cheng Huang, Chunhui Cai, yuwen xie, W. Mao   +19 more
openalex   +1 more source

Image 2_The RET inhibitor pralsetinib suppresses TMZ-resistant glioma growth by regulating spermine production.tif

Lingyun Ma (527380), Hang Gong (4258147), Wei Sun (93580), Jialing Deng (17174362), Qinghua Zhang (145923), Jianzhao Niu (5936966), Huimin Sun (3121266), Xue Han (25073), Tingting Du (9414), Nina Xue (554993), Ming Ji (504536), Qian Liu (135614)   +11 more
openalex   +1 more source

Efficacy and safety of pralsetinib in multiple endocrine neoplasia type 2-associated pheochromocytoma: a case report. [PDF]

Ther Adv Endocrinol Metab
Chen S, Wang H, Shen Q, Han W, Peng K, Kang T, Ou Z, Zhang Z.   +7 more
europepmc   +1 more source

Pralsetinib-Induced Lymphocytic Colitis. [PDF]

ACG Case Rep J
Jin MF, Tawfic SS, Wang XJI.
europepmc   +1 more source

RET-Fusion Positive Advanced Non-Small-Cell Lung Cancer: A Case Report and Review of the Literature [PDF]

, 2021
Mosallaei-Benjamin, Mahshid, Rosenberg, Joshua   +1 more
core  

RET Receptor Tyrosine Kinase Promotes Breast Cancer Metastasis to the Brain and RET Inhibitors Pralsetinib and Selpercatinib Suppress Breast Cancer Brain Metastases [PDF]

Aneglina Regua, Shivani Bindal, Mariana K. Najjar, Phi-Long Tran, Jaehyung Cha, Sedigheh Shams, Hui‐Wen Lo   +6 more
openalex   +1 more source

Pathological complete response in <i>RET</i>-positive non-small cell lung cancer: a case report of pralsetinib-based "sandwich" therapy. [PDF]

Transl Lung Cancer Res
He Q, Xu X, Li D, Zhang Y.
europepmc   +1 more source

The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with RET alterations

, 2021
Steve Duff, Francesca Bargiacchi, Chelsea Norregaard, Melanie Brener, Erin Sullivan   +4 more
openalex   +2 more sources

Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium. [PDF]

Clin Cancer Res
Waliany S, Cooper AJ, Liu SV, Gautschi O, Rotow JK, Smith KER, Weber UM, Lee DH, Loong HHF, Patel JD, Pennell NA, Nagasaka M, Patel SA, Tan DSW, Solomon BJ, Kim TM, Pall G, Riess JW, Sun L, Früh M, Uy NF, Gadgeel S, Feng J, Do A, Falcon C, Leighl NB, Baik CS, Lai GGY, Ou SI, Cheung KSY, Patil T, Mansfield AS, Weiler D, Yeap BY, Wirth LJ, Gainor JF, Drilon A, Lin JJ.   +37 more
europepmc   +1 more source